Clinical efficacy and safety of sublingual immunotherapy in patients with Japanese cedar pollinosis.A double-blind,placebo-controlled study.

Clinical efficacy and safety of sublingual immunotherapy in patients with Japanese cedar pollinosis.A double-blind,placebo-controlled study. - Clinical efficacy and safety of SLIT in patients with Japanese cedar pollinosis.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000709

Enrollment

150

Registered

2007-05-07

Start date

2006-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Japanese cedar pollinosis

Interventions

From September 2006 to May 2008,patients of control 1 receive active treatment once weekly.The induction/build-up phase is 3 weeks,with an increasing daliy number of the extract drops at three consent

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Clinical history of cedar pollen-induced allergic rhinoconjunctivitis for at least 3 years 2)Positive specific IgE to cry j1/2 antigen(CAP-RAST>=class2)

Exclusion criteria

Exclusion criteria: 1)The history of severe asthma 2)The history of anti-allergic drugs within 4 weeks 3)Perior history of immunotherapy with cedar pollen 4)Pregnant women and those at risk of pregnancy 5)Complication of the other nasal-paranasal disease

Design outcomes

Primary

Measure	Time frame
Symptom-medication score	—

Secondary

Measure	Time frame
1)Adverse event 2)Evaluation of biomarker	—

Countries

Japan

Contacts

Public ContactShigetoshi Horiguchi

Chiba University Graduate School Department of Otorhinolaryngology

043-22-7171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026